Update on the Phase 2／3 Clinical Trial of DFP-17729
Filed with TSE · · 1 page · English
Summary by 6ix AI
The current median overall survival among enrolled patients is reported to be approximately seven months, with follow-up expected to conclude by the end of November. No safety issues have been identified so far, and the survival rate among patients remains promising given the poor prognosis typically associated with this condition.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
- Delta-Fly Pharma Inc.: Progress Update of the Phase III Clinical Trial of DFP-14323
- Delta-Fly Pharma Inc. - Notice of initiation of patients enrollment in Phase III Pivotal comparative clinical trial of DFP-14323
- Delta-Fly Pharma Inc.: Abstracts submission for Phase I Clinical Trial of DFP-14927 to 2024 ASCO annual meeting
Earlier from Delta-Fly Pharma
- Delta-Fly Pharma, Inc.: Progress of Development Status of the Combination Study of DFP-10917 with Venetoclax
- Delta-Fly Pharma Inc.: Update for Development Status of the Combination Study of DFP-10917 with Venetoclax
- Delta-Fly Pharma Inc.: Update for Development Status of DFP-17729
- Delta-Fly Pharma Inc.: Progress Update of the Phase III Clinical Trial of DFP-14323
- Delta-Fly Pharma Inc.: Update for Expanded Phase I Study of DFP-14927
Later from Delta-Fly Pharma
All Delta-Fly Pharma news releasesFollow Delta-Fly Pharma into a list and get an email when it puts out news.
Follow Delta-Fly Pharma